MYND Diagnostics was formed to commercialize proprietary biomarker diagnostic tests for patients suffering from MDD, TRD and other psychiatric disorders. VANCOUVER, BC, Oct. 7, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (OTC: MYNDF) (“MYND” or the “Company“) is pleased to announce the formation of its diagnostic biomarker division with the incorporation of a wholly-owned subsidiary…


Previous articlePsygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio
Next articlePTSF80 – Decriminalization in Seattle, San Pedro, and The Dark Web